In an effort to strengthen health outcomes for patients in low resource settings, The Max Foundation and its subsidiary, MaxAid, have signed Collaboration Agreements with 140 individual hematologists and oncologists from leading National Cancer Institutes and clinics in 60 low- and middle-income countries. With the formal establishment of this network, The Max Foundation completes its validated supply chain into each of the countries, providing a safe environment through which to channel humanitarian donations of cancer treatment with end-to-end controls.
“Oncologists and hematologists from these leading cancer centers are the true heroes of our humanitarian treatment access success story,” said Pat Garcia-Gonzalez, CEO of The Max Foundation. “Their dedication to their patients and commitment to our partnership allows us to prevent unnecessary and premature cancer deaths. Working in a challenging environment, their personal contributions go well beyond treatment management and inspire us to do our best to support their patients’ needs.”
Dr. Damira Bayzakova, Kyrgyzstan, adds that “Providing lifesaving treatment to one patient does not save the life of one patient – it saves the lives of the dozens of small children and elderly family members who depend on that patient for their survival.”
The Max Foundation aims to sign collaboration agreements with a total of 350 hematologists and oncologists from more than 70 countries in 2017.
The Max Foundation is a leading global health nonprofit organization dedicated to accelerating health equity. For 28 years, Max has pioneered practical, scalable, high-quality solutions to bring life-extending treatments and patient-centered health care to more than 100,000 people living with cancer and critical illness in low- and middle-income countries. Max believes in a world where all people can access high-impact medicines, where geography is not destiny, and where everyone can strive for health with dignity and with hope.
Since the launch of Max Access Solutions in 2017, The Max Foundation has delivered over 10 million daily doses of cancer treatment to patients in more than 70 low- and middle-income countries.
The Max Foundation is pleased to announce a significant expansion of its collaboration with Pfizer to provide access to some of Pfizer’s innovative oncology portfolio to patients in low- and middle-income countries, which otherwise would have limited local access. The latest agreement increases the total number of patients benefitting from the program from 270 to 500 patients and adds Inlyta® (axitinib) an oral medicine used to treat advanced kidney cancer.
The Max Foundation and Cepheid have renewed and expanded their collaboration to increase access to molecular diagnostics in low- and middle-income countries (LMICs).
